Twist Bioscience Reports Record Revenue and Improved Margins for Q3 2025

Details

The company reported record revenue of $96.1 million, an 18% increase from Q3 2024, marking the 10th consecutive quarter of sequential growth. Gross margin also improved significantly, rising to 53.4% from 43.3% in the same period last year. For the full year fiscal 2025, Twist Bioscience expects revenue to be in the range of $374.0 million to $376.0 million with full-year gross margin guidance raised to 50.5% to 51%. The company anticipates achieving adjusted EBITDA breakeven by the end of fiscal 2026.

Items reported

Exhibits (1)

About Twist Bioscience Corporation

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.